Patient Disease:
Canine Lymphoma
Study Name:
Asparaginase, Procarbazine, Prednisone, and Lomustine (APPL) for Canine Multicentric Lymphoma
Purpose of the study:
- To evaluate the safety and antitumor activity of a combination of the drugs asparaginase, procarbazine, prednisone, and lomustine (APPL) given to dogs with previously untreated lymphoma
Primary Eligibility Criteria:
- Dogs with newly diagnosed lymphoma
- No prior chemotherapy for lymphoma; prior treatment with steroids OK
- Owners must be able to give oral medications to their dog
- Otherwise healthy and free of other major diseases
- Pets must come to CSU for all visits related to the clinical trial
Study Protocol:
- Dogs will receive up to 2 injections of asparaginase under the skin, and will receive oral lomustine (once every 4 weeks), procarbazine, and prednisone (both daily for 2 weeks every 4 weeks) at home
- Rechecks are required weekly for the first 4 weeks after starting then every 4 weeks thereafter
- Dogs will be eligible to continue receiving treatment as long as the drugs are tolerated and they are experiencing clinical benefit (disease stabilization or meaningful tumor shrinkage). Dogs experiencing a complete response (complete disappearance of all evidence of lymphoma) will receive a total of 5 every-4-week “cycles” of treatment, followed by monthly rechecks.
Owner Responsibilities:
- Costs of diagnostics to determine eligibility for clinical trial
- Costs of medications that may be required to treat side effects of treatment
- Make and keep all appointments according to the treatment protocol
Financial Incentives:
- Study covers the costs of some initial testing (flow cytometry, chest X-rays), recheck examinations, blood tests, and chemotherapy
If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.